Tag: treosulfan
-
Medexus Pharmaceutical (MDP.T) readies for powerful year of growth in specialty pharma sector
Big pharma firms like Abbvie can offer incredible product growth potential to investors, but they also saddle shareholders with tremendous risk in terms of regulatory approval and capital cost. According to a recent study which tracked the success rates of clinical drug development through to FDA approval between 2006-2015, just 9.6% of the drug candidates…
-
Medexus (MDP.T) resubmits Treosulfan NDA to FDA
Medexus (MDP.T), a Canadian-based specialty pharma firm focused on acquiring and distributing innovative rare disease treatment solutions in North America, announced today that its strategic partner, medac, had resubmitted its New Drug Application (NDA) for treosulfan to the U.S. Food and Drug Administration. This submission was a response to the FDA request to submit information…
-
Today’s Idea: Medexus Pharmaceuticals (MDP.T) Continues to Climb the North American Pharmaceuticals Ladder
Cancer is a bitch. Even if you haven’t had to battle against cancer yourself, you likely know someone who has. Unfortunately for me, that person was my mom; however, before this turns into a sob story let me assure you that my mom is alive and well after kicking cancer’s ass. My mom was diagnosed…
-
Medexus Pharmaceuticals (MDP.T) gets the Health Canada official nod to commercialize treosulfan
Medexus Pharmaceuticals (MDP.T) received Health Canada’s Notice of Compliance to commercialize treosulfan today, according to a press release. Treosulfan will be sold in Canada using the brand name Trecondyv®. It’s used in combination with another drug called fludarabine as part of a conditioning treatment prior to allogeneic hemapoietic stem cell transplantation. The treatment clears the…